Results 281 to 290 of about 119,169 (307)

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Nature Reviews Clinical Oncology, 2016
Celine Boutros, Ahmad A Tarhini, Olivier Lambotte   +2 more
exaly  

CTLA-4

2006
openaire   +1 more source

Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade

Cell, 2018
Sachet A Shukla, Pavan Bachireddy, Bastian Schilling   +2 more
exaly  

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

Cancer Cell, 2018
Kevin Litchfield, Ehsan Ghorani, Isabelle Solomon   +2 more
exaly  

CTLA-4

2014
openaire   +1 more source

CTLA-4

2011
openaire   +1 more source

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Cancer Cell, 2019
Tuba N Gide, Camelia Quek, Alexander M Menzies   +2 more
exaly  

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

Immunity, 2019
Yunlong Zhao, Xiaozheng Xu, Zhe Huang
exaly  

CTLA-4-MEDIATEDINHIBITION INREGULATION OFT CELLRESPONSES: Mechanisms and Manipulation in Tumor Immunotherapy

Annual Review of Immunology, 2001
Jackson G Egen, James P Allison
exaly  

CTLA-4 nanobody stops colitis

Nature Immunology
openaire   +2 more sources